These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 7792721

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P, Tremblay L, Féger J, Hirsch EC.
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [Abstract] [Full Text] [Related]

  • 24. Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism.
    Picconi B, Centonze D, Rossi S, Bernardi G, Calabresi P.
    Brain; 2004 Jul; 127(Pt 7):1661-9. PubMed ID: 15155524
    [Abstract] [Full Text] [Related]

  • 25. Improved therapies for Parkinson's disease: life beyond dopamine D2/D3 receptor agonists.
    Williams M, Wright S, Lloyd GK.
    Trends Pharmacol Sci; 1997 Sep; 18(9):307-10. PubMed ID: 9345846
    [No Abstract] [Full Text] [Related]

  • 26. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
    Carta AR, Frau L, Pinna A, Pontis S, Simola N, Schintu N, Morelli M.
    Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Rationale for and use of NMDA receptor antagonists in Parkinson's disease.
    Hallett PJ, Standaert DG.
    Pharmacol Ther; 2004 May; 102(2):155-74. PubMed ID: 15163596
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Dopamine receptors--the present state of research and perspectives.
    Wolfarth S, Ossowska K.
    Pol J Pharmacol; 1995 May; 47(3):207-18. PubMed ID: 8714754
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Local application of dopamine inhibits pyramidal tract neuron activity in the rodent motor cortex.
    Awenowicz PW, Porter LL.
    J Neurophysiol; 2002 Dec; 88(6):3439-51. PubMed ID: 12466459
    [Abstract] [Full Text] [Related]

  • 35. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.
    Piercey MF.
    Clin Neuropharmacol; 1998 Dec; 21(3):141-51. PubMed ID: 9617505
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM.
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.